Takuji Okusaka Selected Research

folfirinox

1/2023	A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
8/2022	The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer.
11/2021	A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
10/2018	Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
1/2018	A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
8/2015	Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
2/2015	[Adverse event and countermeasure with regard to FOLFIRINOX for pancreatic cancer].
10/2014	Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takuji Okusaka Research Topics

Disease

100	Neoplasms (Cancer) 03/2024 - 01/2002
95	Pancreatic Neoplasms (Pancreatic Cancer) 02/2024 - 01/2002
85	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 01/2002
46	Biliary Tract Neoplasms (Biliary Tract Cancer) 05/2024 - 12/2002
17	Adenocarcinoma 04/2023 - 01/2002
15	Disease Progression 05/2024 - 03/2007
15	Neutropenia 10/2022 - 04/2004
14	Thrombocytopenia (Thrombopenia) 01/2018 - 02/2005
13	Neoplasm Metastasis (Metastasis) 12/2023 - 04/2004
10	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2021 - 02/2011
8	Hypertension (High Blood Pressure) 04/2024 - 03/2011
8	Leukopenia 04/2024 - 02/2005
8	Ascites 02/2024 - 12/2007
8	Cholangiocarcinoma 11/2023 - 11/2007
8	Anorexia 01/2019 - 04/2008
7	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2022 - 08/2010
6	Liver Diseases (Liver Disease) 05/2024 - 01/2006
6	Fibrosis (Cirrhosis) 06/2022 - 12/2010
6	Carcinoma (Carcinomatosis) 11/2020 - 08/2005
6	Exanthema (Rash) 01/2019 - 02/2011
5	Pathologic Constriction (Stenosis) 03/2024 - 09/2020
5	Fistula 12/2023 - 01/2021
5	Nausea 10/2022 - 04/2008
5	Neuroendocrine Carcinoma 10/2022 - 04/2010
5	Gallbladder Neoplasms (Gallbladder Cancer) 08/2021 - 11/2007
5	Anemia 10/2020 - 02/2011
5	Liver Neoplasms (Liver Cancer) 10/2020 - 05/2012
5	Fatigue 01/2017 - 04/2008
5	Infections 12/2016 - 09/2002
5	Carcinogenesis 01/2016 - 05/2012
4	Hemorrhage 03/2024 - 01/2004
4	Liver Cirrhosis (Hepatic Cirrhosis) 06/2022 - 02/2002
4	Body Weight (Weight, Body) 01/2021 - 01/2005
4	Stomach Neoplasms (Stomach Cancer) 11/2020 - 04/2014
3	Cholangitis 12/2023 - 04/2017
3	Diarrhea 06/2023 - 02/2011
3	Abdominal Pain (Pain, Abdominal) 04/2023 - 03/2011
3	Hepatitis C 06/2022 - 01/2015
3	Stomatitis 01/2019 - 02/2011

Drug/Important Bio-Agent (IBA)

87	Gemcitabine FDA Link 05/2024 - 12/2002
37	Cisplatin (Platino)FDA LinkGeneric 05/2024 - 01/2003
30	Sorafenib (BAY 43-9006)FDA Link 06/2023 - 03/2010
21	Fluorouracil (Carac)FDA LinkGeneric 01/2023 - 02/2002
16	Biomarkers (Surrogate Marker)IBA 06/2022 - 11/2005
15	Proteins (Proteins, Gene)FDA Link 04/2023 - 01/2011
13	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2024 - 11/2002
11	RamucirumabIBA 06/2020 - 07/2015
9	lenvatinibIBA 04/2024 - 03/2016
9	Alanine Transaminase (SGPT)IBA 04/2024 - 02/2005
8	PlatinumIBA 12/2023 - 04/2004
8	Irinotecan (Camptosar)FDA LinkGeneric 01/2023 - 03/2007
8	folfirinoxIBA 01/2023 - 10/2014
7	EnzymesIBA 05/2024 - 09/2004
7	alpha-Fetoproteins (alpha-Fetoprotein)IBA 06/2020 - 01/2006
6	C-Reactive ProteinIBA 12/2023 - 01/2009
6	Peptides (Polypeptides)IBA 01/2021 - 12/2009
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 02/2011
6	BilirubinIBA 10/2019 - 04/2004
6	ProteomeIBA 02/2012 - 11/2005
6	TegafurIBA 03/2011 - 01/2002
5	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2018
5	AlbuminsIBA 02/2024 - 02/2015
5	130-nm albumin-bound paclitaxelIBA 04/2023 - 10/2018
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2023 - 01/2018
5	Antineoplastic Agents (Antineoplastics)IBA 07/2022 - 05/2015
5	Tyrosine Kinase InhibitorsIBA 01/2022 - 02/2011
5	Everolimus FDA Link 11/2021 - 02/2011
5	Monoclonal AntibodiesIBA 01/2021 - 05/2014
5	Protein Subunit VaccinesIBA 01/2021 - 12/2010
5	Epirubicin (Ellence)FDA LinkGeneric 02/2018 - 01/2003
5	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 01/2007
5	UracilIBA 03/2011 - 01/2002
4	durvalumabIBA 05/2024 - 01/2021
4	Leucovorin (Folinic Acid)FDA Link 01/2023 - 10/2018
4	miriplatinIBA 02/2018 - 04/2004
4	Ethiodized Oil (Ethiodol)FDA Link 01/2014 - 01/2002
4	S 1 (combination)IBA 01/2013 - 12/2010
3	AntigensIBA 12/2023 - 09/2004
3	napabucasinIBA 06/2023 - 04/2019
3	MicroRNAs (MicroRNA)IBA 01/2023 - 02/2020
3	Etoposide (VP 16)FDA LinkGeneric 10/2022 - 04/2010
3	Serum AlbuminIBA 06/2022 - 11/2002
3	LigandsIBA 01/2021 - 01/2011
3	GlypicansIBA 01/2021 - 04/2014
3	Axitinib (AG 013736)IBA 01/2021 - 03/2011
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021 - 03/2011
3	Sunitinib (Sutent)FDA Link 06/2019 - 10/2013

Therapy/Procedure

111	Drug Therapy (Chemotherapy) 04/2024 - 01/2002
84	Therapeutics 03/2024 - 12/2002
16	Radiotherapy 07/2023 - 06/2003
14	Stents 03/2024 - 10/2014
11	Combination Drug Therapy (Combination Chemotherapy) 01/2022 - 01/2005
10	Chemoradiotherapy 07/2023 - 01/2004
6	Self Expandable Metallic Stents 02/2024 - 01/2021
6	Adjuvant Chemotherapy 12/2023 - 09/2012
5	Choledochostomy 12/2023 - 01/2021
4	Immunotherapy 11/2023 - 12/2009
4	Palliative Care (Palliative Therapy) 01/2022 - 01/2006
3	Pancreaticoduodenectomy 12/2024 - 09/2012
3	Lasers (Laser) 01/2023 - 11/2005